ROSELLA: Implementation of polygenic risk assessment in general practice for Australia’s most common cancers
Description: Polygenic risk scores (PRSs) are DNA tests that can identify individuals at high risk of Australia’s most common cancers (melanoma, breast, prostate and bowel). The ROSELLA trial aims to test how best we can deliver a PRS multi-cancer risk assessment to all Australians via general practice. If we can make risk assessment available to everyone equitably, we can ensure those most at risk of cancer receive the most appropriate cancer screening for their risk, reducing the burden of cancer for all.
Funder: Medical Research Future Fund
Amount: A$984,200
Funding type: grant
Funder scheme: 2024 Genomics Health Futures
Start date: 2025-06-01
End date: 2027-12-31
Investigator: Sibel Saya
Institution: University of Melbourne
Funded outputs count: 0
Funder award ID: MRF2045030
OpenAlex ID: G678025191